Let's talk about your project!

You are here

Global Innovationin immunotherapy in Toulouse

The IUCT-Oncopole in Toulouse is developing a vaccine that will allow patients suffering from certain types of cancer, such as lung, gastrointestinal or ENT cancers, to be immunised (the equivalent of around 33% of all cancers according to Pr. Jean-Pierre Delord, Managing Director of the IUCT-Oncopole).

In a world first, this vaccine is currently in the experimental development phase and each patient will eventually receive his or her own vaccine: this underscores the excellence of Toulouse and of the IUCT-Oncopole in the field of personalised medicine and biotherapy.

In fact, in 2017 the IUCT-Oncopole achieved the highest possible level of certification with regards to clinical research and biostatistics in oncology (ISO 9001:2015 certification) that has subsequently allowed it to run clinical trials with complex procedures combining high-speed sequencing, big data storage and artificial intelligence (click here for more info - in French). Up until now only two establishments in France have been able to run this type of clinical trial.

Key figures:

  • This innovative treatment was first administered to a patient suffering from an ENT cancer on 15th January 2021.
  • A maximum of around twenty patients will undergo this experimental treatment in 2021.
  • Objectives for 2022: to prove that the patient’s body has developed an immune response to treat the cancer thanks to this vaccine.

This vaccine is currently being developed in conjunction with the Institut Curie in Paris and the biotechnologies company Transgène.

Photo credit: Transgène

> The health sector is doing well in Toulouse!